AstraZeneca

Redx $REDX has enlisted esteemed British exec Lisa Anson to lead the company's do-over as its CEO. Having held management roles at AstraZeneca for 20 years — serving as AstraZeneca UK's president for the last six — Anson, who's also the president of the Association of the British Pharmaceutical ...

(RTTNews.com) - AstraZeneca (AZN.L, AZN) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion, recommending a change to the terms of the Marketing Authorisation for Tagrisso or osimertinib to include the 1st-line ...

Delle Donne and Associates announced Friday that, effective in June, Delaware BioScience Association will move its headquarters from the Delaware Technology Park in Newark to the Fairfax campus Delle Donne purchased last year from the pharmaceutical giant, AstraZeneca, in a deal valued at $50 ...

AstraZeneca has reportedly been given a positive recommendation from the Japanese health ministry for its PD-L1 inhibitor Imfinzi (durvalumab). The positive opinion relates to the firm's application to market the drug as a treatment for stage III non-small cell lung cancer (NSCLC), and the Japanese ...

Esra Erkal-Paler, who heads global external communications at pharmaceutical giant AstraZeneca, is moving to Coty as worldwide corporate affairs officer. The move reflects the return to the beauty products category for the one-time UK/Ireland internal/external communications staffer at L'Oreal Group.

The company was co-founded in 2016 by Michael Davidson, the former CMO of New Jersey-based Omthera, which sold to AstraZeneca for $443 million back in 2013. Davidson and a couple of AstraZeneca scientists launched Corvidia Theapeutics with a drug program it in-licensed from the pharma giant.

A closely watched drug combination of AstraZeneca plc's immunotherapies Imfinzi and tremelimumab fell short of its goal in a Phase 3 study of previously treated lung cancer patients, likely narrowing the regimen's future potential and raising the stakes for a key trial readout later this year. Importantly ...

If there's any readthrough to Mystic, AstraZeneca's first-line trial, it's that Imfinzi still holds promise as a monotherapy, Anderson figures. “We continue to believe that Imfinzi is likely is show an OS benefit in 1L PD-L1(+) patients, and obtain a (modest) foothold in the market,” he wrote. RELATED: 2018 is here.

The FDA's Badrul Chowdhury is moving to AstraZeneca in the same week that he made a series of critical marks against Eli Lilly and Incyte's long-delayed baricitinib, which is set for an adcomm on Monday. His exit also follows a string of FDA personnel jumping to the pharma within the past year, with ...

The Food and Drug Administration has approved AstraZeneca plc's cancer drug Tagrisso for first-line treatment of non-small cell lung cancer (NSCLC) in patients with a mutation known as EGFR, the British pharma said April 18. Approval for the broadened indication is based on results from a Phase 3 study ...

It's only April, but AstraZeneca plc (ADR) (NYSE: AZN) has already had several pieces of good news from their drug pipeline. In January the FDA approved the breast cancer drug Lynparza, which the company was collaborating with Merck Inc (NYSE: MRK) on. In February, its Neurofibromatosis drug ...

AstraZeneca tells Endpoints News that Chowdhury will be moving into a top research job, taking on the role of senior vice president of research development at AstraZeneca and MedImmune, where he will be heading up the Respiratory, Inflammation, and Autoimmunity, Innovative Medicine and Early ...

It's no secret that respiratory drugs make up a crowded field, and forthcoming generics will make the competition tougher still. AstraZeneca's Symbicort is no stranger to the fallout, either, what with payers pressing prices and new rivals grabbing share. But AstraZeneca is fighting back with new ...

The OK, just four months after the agency offered a priority review, marks another big step forward toward AstraZeneca's goal of gaining a larger share of the blockbuster lung cancer market. They recently snagged a pioneering approval for their PD-L1 drug durvalumab in stage III unresectable lung cancer, ...

AstraZeneca PLC (AZN.LN) said on Thursday that the U.S. Food and Drug Administration has approved cancer-drug Tagrisso for the first-line treatment of patients with metastatic non-small cell lung cancer. The pharmaceutical company said that the approval by the FDA is based on results from the ...

Sarah Pope Miksinski, former director of the Office of New Drug Products in FDA's Office of Pharmaceutical Quality, left the agency in February, also for AstraZeneca. And last July, Geoffrey Kim, former director of FDA's Division of Oncology Products moved to AstraZeneca to become its VP of oncology and ...

In an uncertainty-laden industry, IDEA Pharma has come up with one set of metrics to gauge which drug makers are succeeding. And the firm's latest “Pharmaceutical Innovation Index,” (PII) released today, suggests that AstraZeneca, Gilead, and Johnson & Johnson were on the upswing in the past year.

ORLANDO—AstraZeneca may have just found a new niche for blood thinner Brilinta. Sunday at the American College of Cardiology's 67th Annual Scientific Session, the British pharma giant presented data showing the med could match clopidogrel—known in the branded world as Sanofi's Plavix—in terms ...

ORLANDO—When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress. AstraZeneca revealed here Sunday that in a real-world study of more than 400,000 Type 2 diabetes patients, researchers drew an association between treatment with SGLT-2s—including AZ's own Farxiga, ...

The above chart compares revenues and earnings per share (or EPS) for AstraZeneca since 1Q16. AstraZeneca surpassed Wall Street analysts' estimates with EPS of $1.03 on revenues of ~$5.8 billion during 4Q17 as compared to EPS estimates of $0.71 on revenues of ~$5.4 billion during 4Q17.

AstraZeneca PLC (NYSE:AZN) is locked in a heated battle with Tesaro (NASDAQ:TSRO) and Clovis Oncology (NASDAQ:CLVS). The three companies market competing cancer drugs that target poly (ADP-ribose) polymerase (PARP), an enzyme that can repair damaged cancer cells. The market potential ...

When I added AstraZeneca (NYSE:AZN) to my portfolio in mid-2015, it was the second time I'd invested in this well-known pharmaceutical company. The reasons for both ... AstraZeneca appeared to be a fundamentally sound company with a good track record and strong balance sheet. The share price ...

Construction of AstraZeneca's new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019. According to the Cambridge News website, AZ has asked Cambridge City Council's planning committee to allow ...

AstraZeneca $AZN has culled its pipeline of preclinical through mid-stage anti-inflammatory/autoimmune drugs at its big MedImmune subsidiary in Gaithersburg, MD and spun out six programs into a new startup called Viela Bio. Viela springs into existence today with the support of a group of three marquee ...

On Feb. 28, 2018, AstraZeneca announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early stage inflammation and autoimmune programs into an independent biotech company. The new company, named Viela Bio, will focus on developing ...

AstraZeneca's in-the-works Cambridge, U.K., headquarters is already behind schedule, and now, construction may drag on through the middle of next year. The project now won't be wrapped until next May, Cambridge News reports, though the company's still planning to move its employees in before this ...

Harvard Pilgrim Health Care has entered into its third outcomes-based pharmaceutical contract tying what it pays for drugs to how well the patient does on the medicine. In its most recent agreement, the Boston-based not-for-profit insurer has signed an outcomes-based contract for Symbicort, AstraZeneca's ...